FUTURE OF HEALTHCARE

WELL Health Enters into Automatic Share Purchase Plan

WELL Health Technologies Corp. | June 16, 2022

WELL Health

WELL Health Technologies Corp.ca company focused on positively impacting health outcomes by leveraging technology to empower practitioners and their patients globally, announced today that it has entered into an automatic share purchase plancwith a broker in order to facilitate repurchases of the Company's common shares under its previously announced normal course issuer bid. 

WELL previously announced that it had received approval from the Toronto Stock Exchange to, during the 12-month period commencing June 1, 2022 and terminating May 31, 2023, purchase up to 5,555,386 Common Shares, representing approximately 2.5% of the 222,215,443 Common Shares issued and outstanding as of May 30, 2022, by way of a NCIB on the TSX or through alternative trading systems or by such other means as may be permitted under applicable law.

During the effective period of WELL's ASPP, WELL's broker may purchase Common Shares at times when WELL would not be active in the market due to insider trading rules and its own internal trading blackout periods. Purchases will be made by WELL's broker based upon parameters set by WELL when it is not in possession of any undisclosed material information about itself and its securities, and in accordance with the terms of the ASPP. Outside of the effective period of the ASPP, Common Shares may continue to be purchased in accordance with WELL's discretion, subject to applicable law. The ASPP has been entered into in accordance with the requirements of applicable Canadian securities laws.

About WELL Health Technologies Corp.
WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multinational, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and is part of the TSX Composite Index. The Company also trades on the OTCQX Markets under the symbol "WHTCF". 

Spotlight

Telehealth combines telecommunications and health systems to deliver care and support across distances. However, this simple definition belies the complexity of this rapidly evolving field. A cadre of increasingly sophisticated technologies — matched with a need to reduce healthcare costs, serve more patients, and improve quality — drives the field in both high-income and low-income countries. Panelists in this Forum event examined aspects of telehealth in the U.S., including doctor and patient buy-in and the impact of the Affordable Care Act, and in other high-income countries. They also took a look at the role of telehealth in low-income countries, where technologies such as mobile phones can serve as vital tools for healthcare workers to ensure and evaluate standards of care in the diagnosis and treatment of common illnesses.

Spotlight

Telehealth combines telecommunications and health systems to deliver care and support across distances. However, this simple definition belies the complexity of this rapidly evolving field. A cadre of increasingly sophisticated technologies — matched with a need to reduce healthcare costs, serve more patients, and improve quality — drives the field in both high-income and low-income countries. Panelists in this Forum event examined aspects of telehealth in the U.S., including doctor and patient buy-in and the impact of the Affordable Care Act, and in other high-income countries. They also took a look at the role of telehealth in low-income countries, where technologies such as mobile phones can serve as vital tools for healthcare workers to ensure and evaluate standards of care in the diagnosis and treatment of common illnesses.

Related News

HEALTH TECHNOLOGY

Avail Reaches Significant Network Expansion Milestone with the Signing of its 50th MedTech Contract

Avail Medsystems | August 05, 2022

Avail, the digital hub of the operating room enabling the medical technology and healthcare industries to work smarter to advance patient care, announced the addition of a 50th MedTech organization to its telepresence network. With the signing of this contract, the Avail platform is poised to enable hundreds of thousands of people to collaborate, educate, and share surgical and MedTech expertise between operating rooms and remote locations in real time. "The Avail platform was built to connect the MedTech industry more frequently, efficiently and seamlessly to surgeons and interventionalists, enabling them to work together more closely to advance medicine. With this exciting milestone, the digital evolution of MedTech is well underway. Many of our MedTech partners are integrating Avail into their daily processes to expand the productivity and reach of their commercial teams, thus helping representatives to better engage with customers and support their success." Daniel Hawkins, CEO of Avail For some of the world's largest and most respected MedTech companies specializing in devices for neurosurgery, interventional cardiology, interventional radiology, vascular surgery, and orthopedic surgery, among others — Avail has positively changed business practices in myriad ways. These include enabling faster product training and expanded reach for field teams, dramatically increasing the time they have available to sell products and support live procedures. In addition, MedTech companies and surgeons have realized the mutual benefits of using Avail to collaborate during unplanned cases when field representatives are unable to reach remote locations to join in person. With skyrocketing travel costs and staff shortages, Avail's approach to collaboration has allowed physician education and product launch programs not only to continue, but to operate more efficiently and rapidly. Other uses include enabling the acceleration of product innovation by allowing engineering and R&D teams to better connect with providers. "As far as technology goes, the Avail experience has completely raised the bar for our Professional Education Programs — Avail makes us look good," stated John Vogrin, Senior Manager, Surgical Care Services for Cochlear Americas. "But more importantly, using Avail has allowed Cochlear to reduce travel for members of our sales team and give them back countless hours of their personal lives while improving the training experience and shortening the time it takes to complete. It's a win-win-win-win for our company, employees, customers, and their patients." Avail's footprint of consistent, purpose-built hardware in procedure rooms, along with integrated software created for that hardware, serves as the foundation of the company's surgical telepresence platform. The mobile Avail console includes edge-based computing and a large display monitor and is connected securely to the cloud to stream high-quality audio, video, and surgical imaging to remote participants in a HIPAA-HITECH protected environment. "Future-forward MedTech companies and healthcare systems not only need better, faster means of collaboration, but they want a way to share their own software capabilities to and from the OR," stated James Domine, CTO of Avail. "Avail's consistent hardware footprint provides eyes and ears into the operating room and will also enable the sharing of applicable third-party software capabilities, including AI and machine learning, which can be displayed on the large Avail console monitor to further elevate the collaborative experience. This can help improve processes and speed the adoption of new products that better meet the changing healthcare environment." News of the 50th MedTech contract follows Avail's recent announcements of another company expansion and a partnership with the Stroke Thrombectomy and Aneurysm Registry (STAR), which enables participating neurosurgeons to collaborate and share expertise, regardless of their locations. About Avail Medsystems Avail enables the MedTech industry and healthcare providers to work together more often and more efficiently, harnessing expertise and technology in and out of the OR to accelerate the innovation, adoption, and reach of tools and techniques to improve patient care. Avail does this by placing a consistent, mobile, hardware platform with integrated software into operating rooms, audibly and visually connecting remote participants and serving as the hub for advanced digital capabilities including AI and machine learning, in a secure cloud-based digital telepresence network. Today, 50 MedTech organizations have contracted with Avail to rethink commercial models, reduce inefficiencies, and enhance the reach and timeliness of collaboration. Avail was founded in 2017 by MedTech veterans with a vision to leverage Silicon Valley technology expertise to evolve the industry and enable MedTech and healthcare to deliver the best care possible. Avail.io

Read More

HEALTH TECHNOLOGY

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.” Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications. Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901. The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab. Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About ROSALIA6 In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval. About denosumab Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.

Read More

HEALTH TECHNOLOGY

Amazon and One Medical Sign an Agreement for Amazon to Acquire One Medical

One Medical | July 22, 2022

Amazon and One Medical announced that they have entered into a definitive merger agreement under which Amazon will acquire One Medical. One Medical is a human-centered, technology-powered national primary care organization on a mission to make quality care more affordable, accessible, and enjoyable through a seamless combination of in-person, digital, and virtual care services that are convenient to where people work, shop, and live. “We think health care is high on the list of experiences that need reinvention. Booking an appointment, waiting weeks or even months to be seen, taking time off work, driving to a clinic, finding a parking spot, waiting in the waiting room then the exam room for what is too often a rushed few minutes with a doctor, then making another trip to a pharmacy – we see lots of opportunity to both improve the quality of the experience and give people back valuable time in their days. We love inventing to make what should be easy easier and we want to be one of the companies that helps dramatically improve the healthcare experience over the next several years. Together with One Medical’s human-centered and technology-powered approach to health care, we believe we can and will help more people get better care, when and how they need it. We look forward to delivering on that long-term mission.” Neil Lindsay, SVP of Amazon Health Services “The opportunity to transform health care and improve outcomes by combining One Medical’s human-centered and technology-powered model and exceptional team with Amazon’s customer obsession, history of invention, and willingness to invest in the long-term is so exciting,” said Amir Dan Rubin, One Medical CEO. “There is an immense opportunity to make the health care experience more accessible, affordable, and even enjoyable for patients, providers, and payers. We look forward to innovating and expanding access to quality healthcare services, together.” Amazon will acquire One Medical for $18 per share in an all-cash transaction valued at approximately $3.9 billion, including One Medical’s net debt. Completion of the transaction is subject to customary closing conditions, including approval by One Medical's shareholders and regulatory approval. On completion, Amir Dan Rubin will remain as CEO of One Medical. About Amazon Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. About One Medical One Medical is a U.S. national human-centered and technology-powered primary care organization with seamless digital health and inviting in-office care, convenient to where people work, shop, live, and click. One Medical’s vision is to delight millions of members with better health and better care while reducing costs, within a better team environment. One Medical’s mission is to transform health care for all through a human-centered, technology-powered model. Headquartered in San Francisco, 1Life Healthcare, Inc. is the administrative and managerial services company for the affiliated One Medical physician-owned professional corporations that deliver medical services in-office and virtually. 1Life and the One Medical entities do business under the “One Medical” brand.

Read More